Loading…
Loading…
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world's first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesio.
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
CNBC's Jim Cramer urged investors to expand their portfolios beyond the market's hottest AI winners. "I'm not anti-tech.
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for JNJ and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.